Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ('Vivos” or the 'Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused...

Vivos Therapeutics (Nasdaq: VVOS) regains Nasdaq compliance after SOD deal

What happened Vivos Therapeutics, Inc. (Nasdaq: VVOS) said Nasdaq's Listing Qualifications staff told it on October 20, 2026, that it now complies with Rule 5550(b)(1). The rule requires stockholders' equity of at least $2.5 million. The notice came after Vivos closed an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided […]